<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00776516</url>
  </required_header>
  <id_info>
    <org_study_id>178-CL-070</org_study_id>
    <nct_id>NCT00776516</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Interaction Study to Assess the Effect of Repeat Doses of Rifampin on Mirabegron (YM178) in Healthy Volunteers</brief_title>
  <official_title>A Phase 1, Open-Label, Drug Interaction Study to Evaluate the Effect of Repeat Doses of Rifampin on the Single-Dose Pharmacokinetics of Mirabegron (YM178)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to assess the PK, safety and tolerability of a single dose of
      mirabegron alone and in combination with repeat doses of rifampin, a potent CYP3A4 inducer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A single group of patients will receive both mirabegron alone and in combination with
      rifampin
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess pharmacokinetics of mirabegron alone and in combination with rifampin</measure>
    <time_frame>One month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess safety and tolerability of mirabegron alone and in combination with rifampin</measure>
    <time_frame>one month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Pharmacokinetics of YM178</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>mirabegron alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>mirabegron and rifampin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mirabegron</intervention_name>
    <description>oral</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>YM178</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rifampin</intervention_name>
    <description>oral</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Rifadin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Weighs at least 45 kg and body mass index (BMI) between 18 and 32 kg/m2 at Screening

          -  Normal or not clinically significant 12 lead ECG and clinical laboratory test results
             at Screening

          -  Female subjects must be post-menopausal, surgically sterile since at least 1 month
             prior to screening, or practicing effective non-hormonal contraceptive methods. All
             females must be non-lactating, and should have a negative result for the pregnancy
             test at Screening and on Day -1

          -  Negative drug and alcohol screens

        Exclusion Criteria:

          -  Has known or suspected hypersensitivity to mirabegron or rifampin

          -  Liver enzyme test abnormalities (ALT, AST, or bilirubin) above the upper limit of
             normal

          -  History or presence of psychiatric illness, serious active or recurrent infection or
             hepatitis

          -  Previous history of cancer other than basal cell carcinoma or Stage 1 squamous cell
             carcinoma that has not been in remission for at least 5 years prior to the dose of
             study drug

          -  Donation or loss of ≥ 450 mL blood within 56 days prior to study drug administration
             or has donated plasma within 7 days prior to study drug administration

          -  Received or is anticipated to receive a prescription drug within 14 days prior to Day
             -1 or within 30 days prior to Day -1 for any long acting treatments. Use of any
             over-the-counter medications, including complementary and alternative medicines
             (except for occasional use of acetaminophen of up to 2000 mg/day but not more than 4
             days per week) within 14 days prior to Day -1

          -  History of substance abuse within 6 months prior to Screening

          -  Current participation in another clinical trial or is taking or has been taking an
             investigational drug in the 30 days or 10 half lives of the drug, whichever is longer,
             prior to dosing

          -  Known to have hepatitis or HIV-1 and/or HIV-2 or is positive for hepatitis A antibody
             IgM, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody at
             Screening

          -  Subject has consumed alcohol, caffeine-containing food or beverages, grapefruit juice,
             grapefruit-containing products or Seville oranges within 48 prior to Day -1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Central Contact</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Global Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.clinicaltrials.jp/user/ctrDetail_e.jsp?resultId=664</url>
    <description>Link to Results on JAPIC</description>
  </link>
  <reference>
    <citation>Lee J, Moy S, Meijer J, Krauwinkel W, Sawamoto T, Kerbusch V, Kowalski D, Roy M, Marion A, Takusagawa S, van Gelderen M, Keirns J. Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a β3-adrenoceptor agonist. Clin Drug Investig. 2013 Jun;33(6):429-40. doi: 10.1007/s40261-013-0084-y.</citation>
    <PMID>23625188</PMID>
  </reference>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2008</study_first_submitted>
  <study_first_submitted_qc>October 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2008</study_first_posted>
  <last_update_submitted>July 1, 2013</last_update_submitted>
  <last_update_submitted_qc>July 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 3, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy volunteer subjects</keyword>
  <keyword>CYP3A4 inducer</keyword>
  <keyword>rifampin</keyword>
  <keyword>drug interaction</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>YM178</keyword>
  <keyword>mirabegron</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Mirabegron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

